CompletedPhase 4

Effects of Liraglutide on Kidney Function in Type 2 Diabetic Patients

A Randomised, Double-blinded, Cross-over Study Investigating the Short-term Impact of Liraglutide on Kidney Function in Diabetic Patients

Lead sponsor

University of Aarhus

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

Actual enrollment

Study population

Type 2 diabetes

Eligibility highlights

•BMI 20-32•Male

Primary endpoint

•EGFR, change

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01664676

Org study IDU1111-1131-5236

Secondary ID2012-003577-26

Timeline

Milestones

Study first posted2012-08-14estimated

Last update posted2014-02-28estimated

Study start2012-12 (month precision)

Primary completion2014-02actual (month precision)

Study completion2014-02actual (month precision)

Assets

Investigational agents

Liraglutide

Who this study enrolls

Type 2 diabetes

Who can enroll

Minimum age20 Years

Maximum age60 Years

SexMale

Healthy volunteersNot accepted

Inclusion criteria

•Informed consent obtained before any trial-related activities.

•Male gender

•T2DM, diagnosed according to international guidelines

•Age 20-60 years, both included

•Body Mass Index (BMI): 20-32 kg/m2, both included

•Metformin treatment

•Albumin/creatinine ratio <25 mg/mmol

Exclusion criteria

•Known or suspected allergy to trial product or related products

•Previous participation in this trial

•Previous treatment with GLP-1 analogues or DPP-4 inhibitors

•Current treatment with any antidiabetic drug other than metformin

•Poorly regulated glycemic control (HbA1c > 8%)

•Impaired kidney function: estimated GFR < 70ml/min

•Impaired liver function: liver parameters exceed 2 times upper normal limit

•Subjects with active malignancy

•Severe cardiac insufficiency classified according to NYHA III-IV

•Unstable angina pectoris, acute myocardial infarction (AMI) within the last 12 months

•Severe, uncontrolled hypertension: sitting blood pressure (BP) > 180/110 mmHg

•Antihypertensive treatment consisting of more than two different pharmaceutical products

•Symptoms related to benign prostate hyperplasia

•Claustrophobia

•Any metal body implants

•History of pancreatitis, type 1 diabetes, gastroparesis or multiple endocrine neoplasia syndrome type 2

•Personal or family history of medullary thyroid carcinoma

•Any diseases judged by the investigator that could affect the trial

•Any medication judged by the investigator that could affect the trial

Endpoints (5)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Renal / kidney

Safety / tolerability / PK

Renal / kidney

4 endpoints

Primary/protocol endpoint

Glomerular Filtration Rate (51Cr-EDTA plasma clearance)

Time frame:10-15 hours post-dose

eGFR, change

descriptive

Secondary/protocol endpoint

Renal Blood Flow (functional magnetic resonance imaging)

Time frame:15 hours post-dose

descriptive

Secondary/protocol endpoint/low confidence

Renal electrolyte clearance

Time frame:10-15 hours post-dose

descriptive

Secondary/protocol endpoint

Excretion of kidney injury markers

Time frame:0-10 hours and 10-15 hours post-dose

descriptive

componentsalbumin, NGAL, KIM-1, angiotensinogen, 8-OHdG

Safety / tolerability / PK

1 endpoint

Secondary/protocol endpoint

Plasma concentrations of various hormones

Time frame:10-15 hours post-dose

concentration, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.